Key result
Digoxin, ATG7 activators, Resveratrol, and herbal compounds have a comparable effect to Dexrazoxane in preventing anthracycline-induced cardiotoxicity.
Why the study?
Currently, there are no reliable and approved methods for preventing or treating chemotherapy-induced cardiotoxicity, making identification of risk factors and preventive methods vital.
Do Digoxin, ATG7 activators, Resveratrol, and herbal drugs reduce chemotherapy-induced cardiotoxicity in patients receiving antineoplastic therapy?
Systematic Review
Do Digoxin, ATG7 activators, Resveratrol, and herbal drugs reduce chemotherapy-induced cardiotoxicity in patients receiving antineoplastic therapy?
Digoxin, ATG7 activators, and Resveratrol may offer cardioprotective effects comparable to Dexrazoxane against chemotherapy-induced cardiotoxicity.
Suggests potential alternative cardioprotective strategies against anthracyclines; leaves open whether these.
Cancer is a major public health problem, and chemotherapy plays a significant role in the management of neoplastic diseases. However, chemotherapy-induced cardiotoxicity is a serious side effect secondary to cardiac damage caused by antineoplastic's direct and indirect toxicity. Currently, there are no reliable and approved methods for preventing or treating chemotherapy-induced cardiotoxicity. Understanding the mechanisms of chemotherapy-induced cardiotoxicity may be vital to improving survival. The independent risk factors for developing cardiotoxicity must be considered to prevent myocardial damage without decreasing the therapeutic efficacy of cancer treatment. This systematic review aimed to identify and analyze the evidence on chemotherapy-induced cardiotoxicity, associated risk factors, and methods to decrease or prevent it. We conducted a comprehensive search on PubMed, Google Scholar, and Directory of Open Access Journals (DOAJ) using the following keywords: "doxorubicin cardiotoxicity", "anthracycline cardiotoxicity", "chemotherapy", "digoxin decrease cardiotoxicity", "ATG7 activators", retrieving 59 articles fulfilling the inclusion criteria. Therapeutic schemes can be changed by choosing prolonged infusion application over boluses. In addition, some agents like Dexrazoxane can reduce chemotherapy-induced cardiotoxicity in high-risk groups. Recent research found that Digoxin, ATG7 activators, Resveratrol, and other medical substances or herbal compounds have a comparable effect on Dexrazoxane in anthracycline-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Al-Hussaniy et al. (2023) conducted a systematic review in Chemotherapy-induced cardiotoxicity. Digoxin, ATG7 activators, Resveratrol, and herbal drugs vs. Dexrazoxane was evaluated on Prevention or reduction of chemotherapy-induced cardiotoxicity. Digoxin, ATG7 activators, Resveratrol, and herbal compounds have a comparable effect to Dexrazoxane in preventing anthracycline-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: